Volume 75, Issue 2, Pages (February 2019)

Slides:



Advertisements
Similar presentations
Maria Carmen Mir, Cesar Ercole, Andrew Stephenson
Advertisements

Volume 28, Issue 12, Pages (December 2016)
The PSA Era is not Over for Prostate Cancer
Volume 69, Issue 3, Pages (March 2016)
Genetics of common complex diseases: a view from Iceland
Volume 51, Issue 2, Pages (February 2007)
Volume 64, Issue 3, Pages (September 2013)
A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)  Giorgio Arcangeli,
European Urology Focus
Volume 68, Issue 6, Pages (December 2015)
Volume 66, Issue 6, Pages (December 2014)
Volume 63, Issue 5, Pages (May 2013)
Volume 58, Issue 1, Pages (July 2010)
Volume 57, Issue 6, Pages (June 2010)
Volume 199, Issue 4, Pages e235-e236 (April 2018)
Volume 73, Issue 2, Pages (February 2018)
European Urology Oncology
Volume 73, Issue 1, Pages (January 2018)
Volume 61, Issue 5, Pages (May 2012)
Volume 69, Issue 3, Pages (March 2016)
Volume 70, Issue 5, Pages (November 2016)
Volume 68, Issue 3, Pages (September 2015)
Volume 73, Issue 4, Pages (April 2018)
Volume 51, Issue 3, Pages (March 2007)
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Volume 72, Issue 5, Pages (November 2017)
Volume 61, Issue 4, Pages (April 2012)
Volume 63, Issue 4, Pages (April 2013)
Volume 63, Issue 1, Pages (January 2013)
European Urology Oncology
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 61, Issue 5, Pages (May 2012)
Volume 61, Issue 4, Pages (April 2012)
Volume 69, Issue 5, Pages (May 2016)
Volume 72, Issue 6, Pages (December 2017)
Volume 67, Issue 3, Pages (March 2015)
Volume 64, Issue 5, Pages (November 2013)
Volume 61, Issue 6, Pages (June 2012)
Volume 69, Issue 3, Pages (March 2016)
Volume 64, Issue 3, Pages (September 2013)
European Urology Oncology
Volume 57, Issue 4, Pages e41-e42 (April 2010)
Volume 64, Issue 6, Pages (December 2013)
The PSA Era is not Over for Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Volume 71, Issue 6, Pages (June 2017)
Volume 66, Issue 6, Pages (December 2014)
Volume 66, Issue 6, Pages (December 2014)
Mark A. Rubin, Gabriele Girelli, Francesca Demichelis  European Urology 
Volume 72, Issue 4, Pages (October 2017)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Volume 61, Issue 6, Pages (June 2012)
Volume 53, Issue 1, Pages (January 2008)
Volume 69, Issue 6, Pages (June 2016)
Volume 62, Issue 3, Pages (September 2012)
Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA  Nawar Hanna, Quoc-Dien Trinh,
Volume 74, Issue 4, Pages (October 2018)
Volume 21, Issue 3, Pages e4 (September 2017)
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
Bladder Cancer: Highlights from 2006
Volume 54, Issue 2, Pages (August 2008)
Volume 52, Issue 4, Pages (October 2007)
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Volume 53, Issue 6, Pages (June 2008)
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Volume 51, Issue 2, Pages (February 2007)
Volume 67, Issue 4, Pages (April 2015)
Volume 54, Issue 1, Pages (July 2008)
European Urology Oncology
Maximilian Burger, Ashish M. Kamat, David McConkey 
Presentation transcript:

Volume 75, Issue 2, Pages 231-239 (February 2019) Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy  Eugene J. Pietzak, Emily C. Zabor, Aditya Bagrodia, Joshua Armenia, Wenhuo Hu, Ahmet Zehir, Samuel Funt, Francois Audenet, David Barron, Noelia Maamouri, Qiang Li, Min Yuen Teo, Maria E. Arcila, Michael F. Berger, Nikolaus Schultz, Guido Dalbagni, Harry W. Herr, Dean F. Bajorin, Jonathan E. Rosenberg, Hikmat Al-Ahmadie, Bernard H. Bochner, David B. Solit, Gopa Iyer  European Urology  Volume 75, Issue 2, Pages 231-239 (February 2019) DOI: 10.1016/j.eururo.2018.09.002 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Recurrence-free survival (RFS) and overall survival (OS) in patients with primary and secondary MIBC. (A) Comparison of RFS in patients with primary versus secondary MIBC treated with neoadjuvant chemotherapy followed by radical cystectomy. (B) Comparison of OS in patients with primary versus secondary MIBC treated with neoadjuvant chemotherapy followed by radical cystectomy. MIBC=muscle-invasive bladder cancer. European Urology 2019 75, 231-239DOI: (10.1016/j.eururo.2018.09.002) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Genomic analyses of MIBC tumors. (A) Alteration frequency of genes previously associated with chemotherapy response in bladder cancer in primary versus secondary MIBC tumors in the initial genomic analysis. (B) Lollipop plot of ERCC2 missense mutations in primary MIBC in the combined genomic cohort. (C) Oncoprint comparing the frequency of mutations in ERCC2 and the 10 most commonly altered genes between primary and secondary MIBC patients in the prospective validation cohort. Genomic alteration frequencies include novel missense mutations of unknown significance. (D) Volcano plot of the association between mutations and secondary versus primary MIBC in the combined genomic cohort, shown as–log10 p value versus log odds ratio. Results are from exact logistic regression. Bubble size is proportional to the total number of alterations. The horizontal dotted line indicates an unadjusted p value of <0.05. MIBC=muscle-invasive bladder cancer; NAC=neoadjuvant chemotherapy. European Urology 2019 75, 231-239DOI: (10.1016/j.eururo.2018.09.002) Copyright © 2018 European Association of Urology Terms and Conditions